21st Nov 2007 07:02
Deltex Medical Group PLC21 November 2007 Deltex Medical Group plc UCLH and Guys & St Thomas's hospitals use CardioQ(TM)to improve surgical outcomes 21 November 2007 - Deltex Medical Group plc ("Deltex Medical"), the UK's leadinghaemodynamic monitoring company, notes that two major London teaching hospitalshave published initial results from introducing a new approach to major surgeryincluding routine use of the CardioQ. In an article published in Health Director this week Mr Al Windsor, a seniorconsultant colorectal surgeon at University College London Hospital (UCLH)reports on the early implementation of the Enhanced Surgical Treatment andRecovery Programme ESTReP at UCLH and Guys and St Thomas's hospitals. ESTReP,which requires the use of the CardioQ during surgery, was jointly developed byMr Windsor with Mr Andrew Williams, a consultant colorectal surgeon at Guys andSt Thomas's. Mr Windsor states in respect of both Trusts that: "There are improved outcomes for patients, with reduced morbidity rates, fewercomplications and rapid recovery. Length of stay has been reduced fromapproximately 9-10 days per patient to just 6 days." With regard to Mr Windsor's hope that ESTReP will be adopted in other types ofsurgery at UCLH, he goes on to say: "Our hepatic surgery colleagues are interested, and the vascular team is lookingat how it might apply to their patients. There's no reason why it can't berolled out across the board." Deltex Medical's Chief Executive, Andy Hill commented: "UCLH and Guys and St Thomas's are two of the UK's leading teaching hospitalsand amongst the first hospitals in the world to formalise routine use of theCardioQ during surgery. "These excellent results should only encourage other hospitals to follow intheir footsteps. We are already aware of a number of hospitals, both in the UKand overseas, which have been watching closely progress with ESTReP at UCLH andGuys and St Thomas's." For further information, please contact:- Deltex Medical Group plc 01243 774 837 Nigel Keen, Chairman [email protected] Hill, Chief Executive [email protected] Phillips, Finance Director [email protected] Gavin Anderson & Company 020 7554 1400 Deborah Walter [email protected] Speed [email protected] Charles Stanley Securities 020 7149 6457Philip Davies [email protected] Cook [email protected] Notes for Editors Deltex Medical manufactures and markets the CardioQ(TM)monitor, which usesdisposable ultra-sound probes inserted into the oesophagus to determine theamount of blood being pumped around the body - 'circulating blood volume'.Reduced circulating blood volume is known as hypovolaemia, which leads toinsufficient oxygen being delivered to the organs. This causes medicalcomplications including peripheral and major organ failure which can lead todeath. Hypovolaemia, which is akin to severe dehydration, affects virtuallyevery patient having surgery because of the combined effects of pre-operativestarvation, the impact of the anaesthetic agents and trauma from the surgeryitself. Using fluids and drugs, guided by the CardioQ, to optimise the amount ofcirculating blood significantly reduces post-operative complications allowingpatients to make a faster, more complete recovery and return home earlier. The CardioQ incorporates the Company's proprietary software and a smalldiameter, easy-to-use, minimally invasive, disposable oesophageal probe that isused for transmitting and receiving an ultra-sound signal. By using thistechnology, the CardioQ provides clinicians with the ability to haemodynamicallyoptimise critically ill patients and those undergoing routine moderate to majorsurgery through the controlled administration of fluid and drugs. Haemodynamicoptimisation has been scientifically proven to improve the speed and quality ofpatient recovery and reduce hospital stay. There are already over 1,250 CardioQs currently in use in hospitals worldwideand distribution arrangements are in place in over 30 countries. In addition,there are currently more than 90 clinical publications on the use of the CardioQwhich have repeatedly:- • Validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works • Proved that the CardioQ works in a wide range of surgical procedures • Demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients. The SupraQ(TM)is an entirely non-invasive device which uses an ultrasound probeheld at the base of the patient's neck to track the flow of blood in the aorta;it presents the same data as the CardioQ in a similar format and is used fortaking snapshots or monitoring over short periods. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Deltex Medical